Buscopan®
Hyoscine· N- butylbromide
properties :
has a special site of action at the parasympathetic ganglia in the walls of the viscera.Because of this it exerts a specific antispasmodic action on the smooth muscle of the gastro-intestinal, biliary and urinary tracts. No side effects on the central nervous system, the eye, the salivary glands or heart have been observed when Buscopan is administered in therapeutic doses.
Indications:
Gastric and duodenal ulcer,gastro-intestinal spasm and hypermotility, pylorospasm in infants, post-operative vomiting, spastic constipation, biliary dyskinesia and spasm of the urinary tract. Delayed relaxation of the lower uterine segment, dysmenorrhoea.
Dosage:
Adults and school children.The usual dose is 1 – 2 sugar-coated tablets,dessertspoonful liquid or 1 – 2 suppositories (each containing 10 mg) administered 3 – 5 times daily. The dose can be raised at the discretion of the physician. The tablets should be swallowed whole with a little water. The suppositories should be unwrappedand inserted into the rectum pointed end first. In more pronounced conditions of pain 1 ampoule containing 20 mg may be injected
subcutaneously, intramuscularly or intravenously several times daily. In severe biliary and renal colic the slow intravenous injection of “Buscopan compositum” rapidlyrelieves the severe pain.
Infants and young children :
liquid: 1 -2 teaspoonsful t. d.s.
1 paediatric suppository 3 times daily.
In severe case1l 4 of an ampoule 3 times daily.
Availability:
Sugar – coated tablets Box
each containing 10 mg of 20T ablets
liquid containing 1 mg/ml Bottle of 100 ml.
Suppositories containing 10 mg. Box of 6 suppositories
Paediatric suppositories Box of 6 paediatric
containing 7.5 mg suppositories
Ampoules containing 2~ mg Box or6 ampoules
Warning:
Buscopan liquid may cause allergic reaction in some individuals.
Product of :
Chemical Industries Development (CID)
Glza-A. R. E.- G. C. R. 19717
Under licence of:
Boehringer Ingelheim International GmbH
Ingelheim am Rhein – Germany.
